Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.

ABSTRACT:

Background

Omalizumab was approved for the treatment of chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in the United States in March 2014.

Objective

This study sought to describe real-world omalizumab use, in the United States, in a large cohort of patients with CIU/CSU.

Methods

Patients with CIU/CSU (ages ≥12 years) initiated on omalizumab (index date) with ≥12 months of pre- and postindex data were identified in the an insurance claims data base (January 1, 2013, to July 31, 2016). Treatment patterns, including the dosing regimen and continuous use of omalizumab (no gaps for ≥60 days), were described during the 12-month postindex follow-up period.

Results

A total of 1546 patients (mean ± standard deviation [SD] ages, 44 ± 14.5 years; 7

SUBMITTER: Eghrari-Sabet J 

PROVIDER: S-EPMC5911510 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature